SiBone

Si-Bone (NSDQ:SIBN) this week posted third-quarter results that beat the earnings consensus on Wall Street and were in line with revenue estimates.

The Santa Clara, California-based orthopedic implant company reported net losses of $14.2 million, or -41¢ per share, on sales of $26.43 million for the three months ended Sept. 30, for a sales growth of 18.6%. Profit losses were up slightly from Q3 2021 when it reported $15.9 million in losses.

Earnings per share were 7¢ ahead of the Street, where analysts were looking for sales of $26.43 million.

“We are encouraged by the continuing top-line acceleration in our business and the increasing operating leverage we were able to generate in the quarter,” President and CEO Laura Francis said in a news release. “With a record U.S. active surgeon base and growing surgeon enthusiasm for iFuse-Bedrock Granite, I am energized about the long-term potential for the business. As we look beyond 2022, we remain confident th…

Si-Bone (NSDQ:SIBN) this week posted second-quarter results that beat the revenue consensus on Wall Street and missed earnings estimates.

The Santa Clara, California-based company reported losses of $18.5 million, or -54¢ per share, on sales of $25.6 million for the three months ended June 30, for a bottom-line loss of 32.4% on sales growth of 15.28% compared with Q2 2021.

Earnings per share were 6¢ behind The Street, where analysts were looking for sales of $25.17 million.

“I am pleased with the accelerating growth in the U.S. which allowed us to deliver record revenue in the quarter with iFuse-3D and iFuse-Torq as the two best products on the market for MIS SI joint fusion,” CEO Laura Francis said in a news release. “The recent launch of iFuse Bedrock Granite and the expanded trauma indication for iFuse-Torq will complement our core market growth as we support our surgeons in improving patient outcomes across modalities. With the best-in-class portfoli…